Medical bacteria-blocking packaging bag and preparation method thereof

Abstract

The invention relates to the field of medical packaging materials, in particular to a medical bacteria-blocking packaging bag and a preparation method thereof. The medical antibacterial packaging bag is prepared from the following raw materials in percentage by mass: 35 to 45 percent of polypropylene, 10 to 20 percent of modified functional resin, 4 to 11 percent of functional composition, 6 to 12 percent of filler, 1 to 3 percent of antibacterial agent, 1 to 1.5 percent of antioxidant, 0.8 to 1.4 percent of lubricant, 0.5 to 1 percent of nucleating agent, 0.3 to 0.6 percent of antistatic agent and the balance of flexibilizer. The finally prepared packaging bag material not only has excellent antibacterial property and mechanical strength, but also has good barrier property, high temperature resistance, corrosion resistance and the like, so that the use reliability of the medical antibacterial packaging bag is greatly enhanced; the high-performance requirements of existing medical instruments and medicines on the medical packaging bag in the aspect of sterilization compatibility are met, and the medical antibacterial packaging bag has wide medical antibacterial application potential.

Description

Technical Field

[0001] This application relates to the field of medical packaging materials, and more specifically, it refers to a medical bacteria-proof packaging bag and its preparation method. Background Art

[0002] Medical bacteria-proof packaging bags are the core carriers for the sterilization and aseptic preservation of medical devices. Their core function is to provide reliable microbial barrier performance and barrier properties, ensuring that sterilized medical devices are protected from microbial contamination and the intrusion of other microbial-beneficial substances during transportation, storage, and use. With the development of medical technology and the increasing requirements for hospital infection control, such packaging needs to meet multiple requirements simultaneously, such as bacteria-proofness, mechanical strength, barrier properties, high-temperature resistance, and environmental friendliness.

[0003] Early medical packaging mainly used traditional materials such as paper, glass, or metal. However, these materials have many deficiencies, such as being easily damaged, heavy in weight, and not conducive to transportation and storage. In recent years, with the progress of polymer materials science, polyethylene (PE), polypropylene (PP), and some composite materials have been widely used in the manufacture of medical bacteria-proof packaging bags. In particular, the development of multi-layer co-extrusion technology and coating technology has enabled medical packaging bags to not only have excellent physical and mechanical properties but also provide good gas and water vapor barrier properties, effectively extending the shelf life of the packaged contents.

[0004] Although significant progress has been made in the design and manufacture of medical bacteria-proof packaging bags in the existing technology, there are still some challenges. For example, there are performance contradictions among bacteria-proofness, barrier properties, and mechanical strength. There are significant deficiencies in the compatibility of the above properties in the existing packaging bag materials, especially in a high-humidity environment, where the barrier effect will significantly decline. Another example is in terms of sterilization compatibility. After high-temperature and high-pressure or chemical sterilization, the packaging bag materials are prone to phenomena such as deformation, corrosion, breakage, delamination, and chemical residues, which greatly affect the reliability of medical bacteria-proof packaging bags. Summary of the Invention

[0005] Therefore, in order to effectively solve the above technical problems and improve the comprehensive adaptability of medical packaging bags, this application provides a medical bacteria-proof packaging bag and its preparation method. The finally obtained packaging bag material can not only have excellent bacteria-proofness and mechanical strength but also simultaneously take into account good barrier properties, high-temperature resistance, and corrosion resistance, etc., thus greatly enhancing the use reliability of medical bacteria-proof packaging bags. Especially in high-temperature and high-pressure, high-humidity, and chemical sterilization environments, it can still maintain the stability of the mechanical, barrier, and bacteria-proof properties of the packaging bag, meet the high-performance requirements of existing medical devices and drugs for the sterilization compatibility of medical packaging bags, and have broad application potential in medical bacteria-proof applications.

[0006] Medical bacteria-proof packaging bag, by mass percentage, the raw materials are: polypropylene 35-45%, modified functional resin 10-20%, functional composition 4-11%, filler 6-12%, antibacterial agent 1-3%, antioxidant 1-1.5%, lubricant 0.8-1.4%, nucleating agent 0.5-1%, antistatic agent 0.3-0.6%, and the toughening agent makes up the balance.

[0007] As a preferred embodiment, the mass ratio of the polypropylene, modified functional resin and functional composition is (40-45):(15-20):(7-10).

[0008] As a preferred embodiment, the mass ratio of the polypropylene, modified functional resin and functional composition is (43-45):(18-20):(8-9).

[0009] As a preferred embodiment, the melt index of the polypropylene is 18-22 g / 10 min, test conditions: 230 °C / 2.16 kg.

[0010] As a preferred embodiment, the modified functional resin is a modified ethylene-butyl acrylate copolymer resin.

[0011] As a preferred embodiment, the preparation method of the modified ethylene-butyl acrylate copolymer resin specifically includes the following steps: S1: Add the ethylene-butyl acrylate copolymer into xylene, keep the temperature at 120-125 °C, and stir at a speed of 150-180 rpm for 1.5-2 h; S2: Add glycidyl methacrylate, hexafluorobutyl acrylate and 4-vinylpyridine into the reaction system, stir and mix evenly, then add diisopropylbenzene peroxide, heat to 140-145 °C under nitrogen protection and keep warm, and stir and react at a speed of 200-240 rpm for 4-5 h to obtain a pre-product; S3: Transfer the pre-product to a vacuum distillation device, control the vacuum degree at -0.09 to -0.08 MPa and the temperature at 80-85 °C, distill until the solvent residue is ≤0.5%, then naturally cool to room temperature, discharge, pelletize, wash, and finish to obtain the product.

[0012] As a preferred embodiment, the mass ratio of the ethylene-butyl acrylate copolymer, glycidyl methacrylate, hexafluorobutyl acrylate and 4-vinylpyridine is (10-12):(1.5-2):(0.8-1.2):(0.4-0.6).

[0013] As a preferred embodiment, the mass ratio of the ethylene-butyl acrylate copolymer, glycidyl methacrylate, hexafluorobutyl acrylate and 4-vinylpyridine is (10.5-11):(1.6-1.8):(0.8-1):(0.5-0.55).

[0014] As the core matrix of the medical antibacterial packaging material, the modified resin effectively improves the high temperature resistance, high barrier property, superhydrophobicity and antibacterial synergy of the material, meeting the stringent requirements of medical packaging for sterilization tolerance, antibacterial property and long-term stability. The rigid pyridine ring of vinylpyridine in the modified resin is embedded in the polymer main chain, restricting the movement of molecular segments, significantly increasing the glass transition temperature, and assisting the epoxy groups in the modified resin to undergo cross-linking reactions at high temperatures to form a three-dimensional network structure, enhancing the thermal stability. On the other hand, the fluorine segments contained in the resin reduce the free volume of the polymer, hinder the diffusion of oxygen molecules, and generate dipole-dipole repulsion with oxygen molecules through the enhanced polarity after modification. Acting together with the functional composition added in this application, a dense interpenetrating network is formed to synergistically block the gas permeation path, and finally a denser surface cross-linking structure is formed, promoting the enrichment of fluorinated side chains on the material surface to form a low surface energy layer, greatly improving the barrier property while maintaining excellent corrosion resistance and waterproof performance, ensuring the functionality of internal functional components under long-term use and high temperature and high humidity environments, thus guaranteeing the overall performance of the medical antibacterial packaging bag.

[0015] As a preferred embodiment, the functional composition is a composition of polyvinyl alcohol, polyvinylidene chloride and quaternary ammonium chitosan.

[0016] As a preferred embodiment, the mass ratio of polyvinyl alcohol, polyvinylidene chloride and quaternary ammonium chitosan is (4 - 5):(2 - 3):(2 - 3).

[0017] As a preferred embodiment, the mass ratio of polyvinyl alcohol, polyvinylidene chloride and quaternary ammonium chitosan is (4.2 - 4.5):(2.5 - 3):(2.1 - 2.4).

[0018] As a preferred embodiment, the degree of deacetylation of the quaternary ammonium chitosan is ≥90%.

[0019] As a preferred embodiment, the degree of polymerization of the polyvinyl alcohol is 1700 - 1800.

[0020] As a preferred embodiment, the filler is a composition of talc powder and sericite powder.

[0021] As a preferred embodiment, the mass ratio of talc powder and sericite powder is (2.8 - 3.4):(1.8 - 2.5).

[0022] As a preferred embodiment, the average particle size of the talc powder is 2.5 - 3.5 μm.

[0023] As a preferred embodiment, the average particle size of the sericite powder is 2 - 4 μm.

[0024] As a preferred embodiment, the antibacterial agent is a composition of nano zinc oxide and silver ion-loaded zeolite.

[0025] As a preferred embodiment, the mass ratio of the nano zinc oxide to the silver ion-loaded zeolite is (2.5 - 3):(0.4 - 0.6).

[0026] As a preferred embodiment, the antioxidant is at least one of Irganox 1010, Irganox 1076, phosphite ester, and tocopherol.

[0027] As a preferred embodiment, the antioxidant is Irganox 1010 or Irganox 1076.

[0028] As a preferred embodiment, the lubricant is at least one of calcium stearate, oxidized polyethylene wax, calcium stearate, and ethylene bisstearamide.

[0029] As a preferred embodiment, the lubricant is calcium stearate.

[0030] As a preferred embodiment, the nucleating agent is a composition of sodium benzoate and sorbitol benzylidene derivative.

[0031] As a preferred embodiment, the mass ratio of the sodium benzoate to the sorbitol benzylidene derivative is (1.5 - 1.8):(1 - 1.2).

[0032] As a preferred embodiment, the antistatic agent is at least one of ethoxylated alkylamine, polyether ester amide, and glycerol monostearate.

[0033] As a preferred embodiment, the antistatic agent is ethoxylated alkylamine.

[0034] As a preferred embodiment, the toughening agent is at least one of SEBS, POE, TPU, and acrylate elastomer.

[0035] As a preferred embodiment, the toughening agent is SEBS.

[0036] The preparation method of the above-mentioned medical bacteria-proof packaging bag specifically includes the following steps: S1: Add the functional composition, antibacterial agent, antioxidant, lubricant, nucleating agent, antistatic agent and toughening agent into a high-speed mixer and mix at 60-65°C and a rotation speed of 800-1000 rpm for 15-20 minutes to obtain a mixed auxiliary agent; S2: Add the mixture of polypropylene and modified functional resin, filler, and mixed auxiliary agent into a twin-screw extruder in three batches. The temperature zones are set as zone 1 at 180-185°C, zone 2 at 190-195°C, zone 3 at 195-200°C, zone 4 at 200-205°C, zone 5 at 195-200°C, die head at 190-195°C, screw rotation speed of 300-350 rpm, and vacuum devolatilization at -0.09 to -0.08 MPa. Then extrude, water-cool, draw and pelletize, and dry in a blast dryer at 80-85°C for 3-4 hours until the moisture content ≤ 0.1% to obtain the base material; S3: Add the base material into a single-screw blown film unit and blow film under the conditions of die head temperature of 205-210°C, screw rotation speed of 60-65 rpm, traction speed of 15-18 m / min, and blow-up ratio of 2-2.5. After completion, wind up with constant tension to ensure that the film roll has no wrinkles, and then it is obtained.

[0037] The beneficial effects of this application are:

[0038] 1. For the medical bacteria-proof packaging bag provided in this application, the finally obtained packaging bag material not only has excellent bacteria-proof property and mechanical strength, but also can simultaneously take into account good barrier property, high-temperature resistance and corrosion resistance, etc., thus greatly enhancing the use reliability of the medical bacteria-proof packaging bag. Especially in high-temperature and high-pressure, high-humidity and chemical sterilization environments, it can still maintain the stability of the mechanical, barrier and bacteria-proof properties of the packaging bag, meet the high-performance requirements of existing medical devices and drugs for the sterilization compatibility of medical packaging bags, and has broad application potential for medical bacteria-proof.

[0039] 2. For the medical bacteria-proof packaging bag provided in this application, the added modified resin serves as the core matrix of the medical bacteria-proof packaging material, effectively improving the high-temperature resistance, high-barrier property, super-hydrophobicity and antibacterial synergistic effect of the material, and meeting the strict requirements of medical packaging for sterilization tolerance, bacteria-proof property and long-term stability. The rigid pyridine ring of vinylpyridine in the modified resin is embedded in the polymer main chain, restricting the movement of molecular segments, significantly increasing the glass transition temperature, and assisting the epoxy groups in the modified resin to undergo cross-linking reactions at high temperatures to form a three-dimensional network structure, enhancing thermal stability, barrier property and waterproof property.

[0040] 3. A medical bacteria-blocking packaging bag provided in the present application generates dipole-dipole repulsion with oxygen molecules through the polarity enhancement effect of the modified resin, and jointly acts with the functional composition added in the present application to form a dense interpenetrating network, synergistically blocking the gas permeation path, and finally forming a denser surface cross-linked structure, promoting the enrichment of fluorinated side chains on the material surface to form a low surface energy layer, greatly improving the barrier property while maintaining excellent corrosion resistance and waterproof performance, ensuring the functionality of the internal functional components under long-term use and high-temperature and high-humidity environments, thereby ensuring the overall performance of the medical bacteria-blocking packaging bag. Detailed implementation manners

[0041] In the detailed implementation manners, specific implementation cases will be used to more intuitively display and explain the content in the invention content of the present application. And the following embodiments are only actual examples for explaining and interpreting the technical solutions in the specification, and should not limit the scope of the claims to be protected by the present application.

[0042] Example 1

[0043] For the medical bacteria-blocking packaging bag, by mass percentage, the raw materials are: 45% of polypropylene, 20% of modified functional resin, 8% of functional composition, 10% of filler, 2.8% of antibacterial agent, 1.3% of antioxidant, 0.9% of lubricant, 0.6% of nucleating agent, 0.3% of antistatic agent, and the balance is made up by a toughening agent.

[0044] The melt index of the polypropylene is 20 g / 10 min, test conditions: 230 °C / 2.16 kg, and it is a product of T30S model purchased from China National Petroleum & Chemical Corporation.

[0045] The modified functional resin is a modified ethylene-butyl acrylate copolymer resin. By mass parts, the preparation method specifically includes the following steps: S1: Add 10.8 parts of ethylene-butyl acrylate copolymer to 25 parts of xylene, keep the temperature at 120 °C, and stir at a speed of 150 rpm for 1.5 h; S2: Add 1.8 parts of glycidyl methacrylate, 0.9 parts of hexafluorobutyl acrylate, and 0.52 parts of 4-vinylpyridine to the reaction system, stir and mix evenly, then add 0.008 parts of diisopropylbenzene peroxide, heat to 140 °C under nitrogen protection and keep warm, and stir and react at a speed of 200 rpm for 5 h to obtain a pre-product; S3: Transfer the pre-product to a vacuum distillation device, control the vacuum degree at -0.09 MPa and the temperature at 80 °C, distill until the solvent residue is ≤ 0.5%, then naturally cool to room temperature, discharge, cut into pellets and wash, and it is ready after completion.

[0046] The functional composition is a composition of polyvinyl alcohol-1788, polyvinylidene chloride, and chitosan quaternary ammonium salt, and the mass ratio is 4.5:2.8:2.2.

[0047] The polyvinylidene chloride was purchased as Dow Saran sold by Dow Chemical Company, USA. TM Product of Model 806.

[0048] The degree of deacetylation of the quaternary ammonium salt of chitosan was 92%, and it was purchased as a packaged premium product sold by Wuhan Lanabai Pharmaceutical Chemical Co., Ltd.

[0049] The filler was a composition of talc powder and sericite powder, and the mass ratio was 3:2.

[0050] The average particle size of the talc powder was 2.8 μm, and the average particle size of the sericite powder was 3.1 μm.

[0051] The antibacterial agent was a composition of nano-zinc oxide and silver ion-loaded zeolite, and the mass ratio was 2.5:0.5. The silver ion-loaded zeolite was purchased as a product of a certain model sold by Toray Industries, Inc., Japan.

[0052] The antioxidant was Irganox 1010; the lubricant was calcium stearate.

[0053] The nucleating agent was a composition of sodium benzoate and the sorbitol benzylidene derivative Millad 3988, and the mass ratio was 1.6:1.

[0054] The antistatic agent was ethoxylated alkylamine; the toughening agent was SEBS, purchased as a product of Model G1651 sold by Kraton Corporation, USA.

[0055] The preparation method of the medical bacteria-proof packaging bag specifically included the following steps: S1: Add the functional composition, antibacterial agent, antioxidant, lubricant, nucleating agent, antistatic agent and toughening agent into a high-speed mixer and mix at 60 °C and a rotation speed of 800 rpm for 20 min to obtain a mixed auxiliary agent; S2: Feed the mixture of polypropylene and modified functional resin, filler, and mixed auxiliary agent into a twin-screw extruder in three batches. The temperature zones were set as Zone 1 at 185 °C, Zone 2 at 195 °C, Zone 3 at 200 °C, Zone 4 at 205 °C, Zone 5 at 200 °C, the die head at 195 °C, the screw rotation speed at 320 rpm, and vacuum devolatilization at -0.08 MPa. Then extrude, water-cool, draw into strands and cut into pellets, and dry in a blast dryer at 80 °C for 4 h until the moisture content ≤ 0.1% to obtain the base material; S3: Add the base material into a single-screw blown film unit, and blow film under the conditions of a die head temperature of 210 °C, a screw rotation speed of 60 rpm, a traction speed of 15 m / min, and a blow-up ratio of 2.2. After completion, wind up with constant tension to ensure that the film roll has no wrinkles, and then it is obtained.

[0056] Example 2

[0057] This example only has the following differences from Example 1: For the medical bacteria-proof packaging bag, by mass percentage, the raw materials are: 42% polypropylene, 17% modified functional resin, 8% functional composition, 12% filler, 2.8% antibacterial agent, 1.3% antioxidant, 0.9% lubricant, 0.6% nucleating agent, 0.3% antistatic agent, and the balance is made up by the toughening agent.

[0058] The functional composition is a composition of polyvinyl alcohol - 1788, polyvinylidene chloride and chitosan quaternary ammonium salt, and the mass ratio is 5:2:3.

[0059] Example 3

[0060] This example only has the following differences from Example 1: For the medical bacteria-proof packaging bag, by mass percentage, the raw materials are: 40% polypropylene, 18% modified functional resin, 10% functional composition, 9% filler, 2.8% antibacterial agent, 1.3% antioxidant, 0.9% lubricant, 0.6% nucleating agent, 0.3% antistatic agent, and the balance is made up by the toughening agent.

[0061] The functional composition is a composition of polyvinyl alcohol - 1788, polyvinylidene chloride and chitosan quaternary ammonium salt, and the mass ratio is 4:3:2.

[0062] Comparative Example 1

[0063] This comparative example only has the following differences from Example 1: For the medical bacteria-proof packaging bag, by mass percentage, the raw materials are: 60% polypropylene, 10% modified functional resin, 3% functional composition, 10% filler, 2.8% antibacterial agent, 1.3% antioxidant, 0.9% lubricant, 0.6% nucleating agent, 0.3% antistatic agent, and the balance is made up by the toughening agent.

[0064] Comparative Example 2

[0065] This comparative example only has the following differences from Example 1: For the medical bacteria-proof packaging bag, by mass percentage, the raw materials are: 52% polypropylene, 20% modified functional resin, 1% functional composition, 10% filler, 2.8% antibacterial agent, 1.3% antioxidant, 0.9% lubricant, 0.6% nucleating agent, 0.3% antistatic agent, and the balance is made up by the toughening agent.

[0066] Comparative Example 3

[0067] This comparative example only has the following differences from Example 1: The functional composition is a composition of polyvinyl alcohol - 1788, polyvinylidene chloride and chitosan quaternary ammonium salt, and the mass ratio is 8:1:1.5.

[0068] Comparative Example 4

[0069] This comparative example and Example 1 only have the following differences: The functional composition is a composition of polyvinyl alcohol-1788, polyvinylidene chloride and chitosan quaternary ammonium salt, and the mass ratio is 1:3:3.

[0070] Comparative Example 5

[0071] This comparative example and Example 1 only have the following differences: The modified functional resin is a modified ethylene-butyl acrylate copolymer resin. By mass, the preparation method specifically includes the following steps: S1: Add 20.5 parts of ethylene-butyl acrylate copolymer to 40 parts of xylene, keep the temperature at 120 °C, and stir at a speed of 150 rpm for 1.5 h; S2: Add 1.1 parts of glycidyl methacrylate, 0.4 parts of hexafluorobutyl acrylate and 0.2 parts of 4-vinylpyridine to the reaction system. After stirring and mixing evenly, add 0.006 parts of diisopropylbenzene peroxide, heat up to 140 °C under nitrogen protection and keep warm, and stir and react at a speed of 200 rpm for 5 h to obtain a pre-product; S3: Transfer the pre-product to a vacuum distillation device, control the vacuum degree to -0.09 MPa and the temperature to 80 °C, distill until the solvent residue is ≤ 0.5%, then naturally cool to room temperature, discharge, pelletize and wash to complete.

[0072] Comparative Example 6

[0073] This comparative example and Example 1 only have the following differences: The modified functional resin is a modified ethylene-butyl acrylate copolymer resin. By mass, the preparation method specifically includes the following steps: S1: Add 4.8 parts of ethylene-butyl acrylate copolymer to 20 parts of xylene, keep the temperature at 120 °C, and stir at a speed of 150 rpm for 1.5 h; S2: Add 2.4 parts of glycidyl methacrylate, 1.1 parts of hexafluorobutyl acrylate and 0.85 parts of 4-vinylpyridine to the reaction system. After stirring and mixing evenly, add 0.008 parts of diisopropylbenzene peroxide, heat up to 140 °C under nitrogen protection and keep warm, and stir and react at a speed of 200 rpm for 5 h to obtain a pre-product; S3: Transfer the pre-product to a vacuum distillation device, control the vacuum degree to -0.09 MPa and the temperature to 80 °C, distill until the solvent residue is ≤ 0.5%, then naturally cool to room temperature, discharge, pelletize and wash to complete.

[0074] Performance Evaluation

[0075] 1. Refer to the standard ASTM E96 for water vapor transmission rate testing, and take the average value of 10 tests and record it in Table 1.

[0076] 2. Refer to the standard ASTM D5946 for surface water contact angle testing, and take the average value of 10 tests and record it in Table 1.

[0077] 3. Refer to the standard ASTM D638 for tensile strength testing, and take the average value of 10 tests and record it in Table 1.

[0078] 4. Place the packaging bag film layer materials prepared in the examples and comparative examples into an oven at 150 ± 3 °C for 1 h, measure the transverse shrinkage rate of the film layer materials after testing, and record the average value of 10 tests in Table 1.

[0079] 5. Conduct a corrosion resistance test with reference to standard ASTM D543, take the retention rate of tensile strength after testing, and record the average value of 10 tests in Table 1.

[0080] Table 1 Results of performance evaluation

[0081]

[0082] Judging from the final performance test results of the examples and comparative examples, Comparative Examples 1-6 achieved worse performance results compared to the examples. The examples, by compounding a modified resin with more excellent performance and a functional composition, jointly formed a dense interpenetrating network, synergistically blocked the gas permeation path, and finally formed a denser surface cross-linked structure, promoting the enrichment of fluorinated side chains on the material surface to form a low surface energy layer. While significantly improving the barrier property, it maintained excellent corrosion resistance and waterproof performance, ensuring the functionality of the internal functional components in the long-term use and high-temperature and high-humidity environment, thus guaranteeing the overall performance of the medical bacteria-proof packaging bag.

Claims

1. A medical antibacterial packaging bag, characterized in that: The raw materials are, by mass percentage, 35-45% polypropylene, 10-20% modified functional resin, 4-11% functional composition, 6-12% filler, 1-3% antibacterial agent, 1-1.5% antioxidant, 0.8-1.4% lubricant, 0.5-1% nucleating agent, 0.3-0.6% antistatic agent, and the balance of toughening agent. The melt index of the polypropylene is 18-22 g / 10 min, and the test conditions are: 230° C. / 2.16 kg; The modified functional resin is a modified ethylene-butyl acrylate copolymer resin; The functional composition is a composition of polyvinyl alcohol, polyvinylidene chloride and chitosan quaternary ammonium salt, with a mass ratio of (4-5): (2-3): (2-3); The filler is a composition of talc powder and sericite powder, with a mass ratio of (2.8-3.4): (1.8-2.5).

2. The medical antibacterial packaging bag according to claim 1, characterized in that: The mass ratio of the polypropylene, the modified functional resin and the functional composition is (40-45): (15-20): (7-10).

3. The medical antibacterial packaging bag according to claim 2, characterized in that: The preparation method of the modified ethylene-butyl acrylate copolymer resin specifically comprises the following steps: S1: adding ethylene-butyl acrylate copolymer to xylene, maintaining a constant temperature of 120-125° C., and stirring at a speed of 150-180 rpm for 1.5-2 hours; S2: adding glycidyl methacrylate, hexafluorobutyl acrylate and 4-vinyl pyridine to the reaction system, stirring and mixing evenly, and then adding dicumyl peroxide, heating to 140-145° C. under nitrogen protection and maintaining the temperature, stirring at a speed of 200-240 rpm for reaction for 4-5 hours, and obtaining a pre-product after completion; S3: transferring the pre-product to a reduced pressure distillation device, controlling the vacuum degree to -0.09-0.08 MPa, the temperature to 80-85° C., distilling to a solvent residual content of ≤0.5%, then naturally cooling to room temperature, discharging, pelletizing and washing, and obtaining the product.

4. The medical antibacterial packaging bag according to claim 3, characterized in that: The mass ratio of the ethylene-butyl acrylate copolymer, glycidyl methacrylate, hexafluorobutyl acrylate and 4-vinyl pyridine is (10-12): (1.5-2): (0.8-1.2): (0.4-0.6).

5. The medical antibacterial packaging bag according to claim 4, characterized in that: The average particle size of the talc powder is 2.5 to 3.5 μm; the average particle size of the sericite powder is 2 to 4 μm.

6. The medical antibacterial packaging bag according to claim 5, characterized in that: The antibacterial agent is a composition of nano zinc oxide and silver ion-carrying zeolite, with a mass ratio of (2.5-3): (0.4-0.6).

7. The medical antibacterial packaging bag according to claim 6, characterized in that: The nucleating agent is a composition of sodium benzoate and a sorbitol benzyl derivative, and the mass ratio is (1.5-1.8): (1-1.2).

8. The medical antibacterial packaging bag according to claim 7, characterized in that: The antistatic agent is at least one of ethoxylated alkylamine, polyetheresteramide and glycerol monostearate.

9. The medical antibacterial packaging bag according to claim 8, characterized in that: The toughening agent is at least one of SEBS, POE, TPU and acrylic elastomer.

10. A method for preparing a medical bacteria-barrier packaging bag according to any one of claims 1 to 9, characterized in that: The specific steps include: S1: adding the functional composition, antibacterial agent, antioxidant, lubricant, nucleating agent, antistatic agent and toughening agent into a high-speed mixer and mixing at 60-65°C and 800-1000rpm for 15-20min to obtain a mixing aid; S2: adding the mixture of polypropylene and modified functional resin, filler and mixing aid into a twin-screw extruder in three times, setting the temperature zones as 180-185°C for zone 1, 190-195°C for zone 2, 195-200°C for zone 3, 200-205°C for zone 4, 195-200°C for zone 5, 190-195°C for die head, 300-350rpm for screw speed, -0.09--0.08MPa vacuum devolatilization, then extruding water-cooled strands and pelletizing, and drying at 80-85°C with forced air for 3-4h until the moisture content is ≤0.1% to obtain a base material; S3: Add the base material into the single-screw film blowing unit, and blow the film under the conditions of die head temperature of 205-210℃, screw speed of 60-65rpm, traction speed of 15-18m / min, and blowing ratio of 2-2.

5. After completion, use constant tension to wind up to ensure that the film roll has no wrinkles.

Images